JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 4 May 2007. doi:10.1136/jcp.2006.044891
Journal of Clinical Pathology 2007;60:1384-1391
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jcp.2006.044891v1
60/12/1384    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Riley, P
Right arrow Articles by Crook, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Riley, P
Right arrow Articles by Crook, M

VIRUSES AND LYMPHOMAS

A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease

P Riley1, J O’Donohue1, M Crook2

1 Department of Gastroenterology, University Hospital Lewisham, London, UK
2 Department of Biochemistry, University Hospital Lewisham, London, UK

Correspondence to:
Mr P Riley, Department of Gastroenterology, University Hospital Lewisham, Lewisham High Street, London SE13 6LH, UK; paul.riley{at}kcl.ac.uk

Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic disorder in western countries, and its incidence is increasing. This review outlines the significant health burden posed by NAFLD and discusses what is presently known about its pathogenesis, including the roles of the metabolic syndrome, obesity, insulin resistance, hepatic steatosis, reactive oxygen species, inflammatory cytokines and adipocytokines. The way in which NAFLD is clinically diagnosed is described, and areas of uncertainty surrounding its investigation are identified, before discussing the relative merits of the limited treatment options available and looking ahead to potential therapeutic strategies for the future.








HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.